AbbVie vs Mondelēz International

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...

Mondelēz International Announces Toblerone Diamond Truffles with Biscoff®, Uniting Two Global Icons in a Premium Chocolate Experience

Toblerone Diamond Truffles with Biscoff® combine smooth Toblerone milk chocolate, rich Biscoff® spread filling, and crunchy honey-almond nougat pieces in a distinctive diamond shape. Available in two formats: a 495g premium box exclusive to Costco across ten markets, and a 180g sharing box in select countries. Marks the first global retail partnership between Mondelēz International and Costco.

10-Q Financial Filing Analysis for Mondelēz International (2026-07-28)

For the second quarter ended June 30, 2026, Mondelēz International reported net revenues of $9.36 billion, an increase of 4.1% year-over-year (with Organic Net Revenue growing 2.2%), driven by carryover pricing and volume/mix gains across emerging markets. Operating income rose 66.0% to $1.95 billion, and net earnings attributable to Mondelēz reached $1.55 billion ($1.20 diluted EPS), substantially elevated by mark-to-market derivative gains of $827 million and lower pension settlement costs compared to the prior-year period. However, Adjusted Operating Income decreased 4.8% to $1.22 billion (and down 6.1% on constant currency) due to higher raw material input costs, pricing elasticity headwinds in Europe, and ERP transformation expenditures.

• Net revenues for Q2 2026 increased 4.1% to $9,355 million, with Organic Net Revenue rising 2.2% driven by 1.5 pp of pricing and 0.7 pp of volume/mix.
• Reported operating income reached $1,946 million (20.8% margin) up from $1,172 million, boosted by $827 million in mark-to-market derivative gains, while Adjusted Operating Income declined 4.8% to $1,222 million.
• Quarterly cash dividend was raised by 4% to $0.52 per share of Class A Common Stock, payable on October 14, 2026, with $6.5 billion remaining under the share repurchase program.